"We like Lexicon. The company has plenty of cash, a robust, late stage pipeline and one of big pharma’s leading names behind, and in front of, a potentially multi billion-dollar product. At its current $1.2 billion valuation, there’s not much room for immediate upside, but if the company can pick up a green light from the FDA in either of its two current diabetes target indications, this room will widen considerably and Lexicon will become a multi-billion dollar pharma producer. "
News 
Market Data 
Discover 
